BidaskClub upgraded shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) from a buy rating to a strong-buy rating in a research report report published on Thursday.

Several other equities research analysts have also commented on BHVN. Zacks Investment Research raised shares of Biohaven Pharmaceutical Holding Co from a sell rating to a hold rating in a report on Monday, August 28th. Morgan Stanley lifted their price objective on Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the company an overweight rating in a research note on Monday, September 25th. Needham & Company LLC reissued a buy rating and issued a $43.00 price objective (up previously from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, September 13th. Finally, Piper Jaffray Companies reissued a buy rating and issued a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, September 12th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Biohaven Pharmaceutical Holding Co presently has a consensus rating of Buy and an average price target of $44.00.

Shares of Biohaven Pharmaceutical Holding Co (BHVN) opened at 37.38 on Thursday. Biohaven Pharmaceutical Holding Co has a 12-month low of $17.00 and a 12-month high of $39.51. The firm’s 50-day moving average price is $31.72 and its 200 day moving average price is $26.70. The company’s market cap is $1.34 billion.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/biohaven-pharmaceutical-holding-co-ltd-bhvn-stock-rating-upgraded-by-bidaskclub/1602559.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.